MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/ju.0000000000003188

Медицинская библиотека · The Journal of urology · 2023

A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study.

Ghoreifi Alireza, Ladi-Seyedian Seyedeh-Sanam, Piatti Paolo, Chew Yap Ching, Jara Benjamin, Sanossian Lucy, Bhasin Jeffrey M, Yamada Taikun, Fuchs Gerhard, Bhanvadia Sumeet, Sotelo Rene, Hung Andrew, Aron Monish, Desai Mihir, Gill Inderbir, Daneshmand Siamak, Liang Gangning, Djaladat Hooman

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: We explored the accuracy of a urine-based epigenetic test for detecting upper tract urothelial carcinoma.

MATERIALS AND

METHODS

Under an Institutional Review Board-approved protocol, urine samples were prospectively collected from primary upper tract urothelial carcinoma patients before radical nephroureterectomy, ureterectomy, or ureteroscopy between December 2019 and March 2022. Samples were analyzed with Bladder CARE, a urine-based test that measures the methylation levels of 3 cancer biomarkers (TRNA-Cys, SIM2, and NKX1-1) and 2 internal control loci using methylation-sensitive restriction enzymes coupled with quantitative polymerase chain reaction. Results were reported as the Bladder CARE Index score and quantitatively categorized as positive (>5), high risk (2.5-5), or negative (<2.5). The findings were compared with those of 1:1 sex/age-matched cancer-free healthy individuals.

RESULTS

Fifty patients (40 radical nephroureterectomy, 7 ureterectomy, and 3 ureteroscopy) with a median (IQR) age of 72 (64-79) years were included. Bladder CARE Index results were positive in 47, high risk in 1, and negative in 2 patients. A significant correlation was found between Bladder CARE Index values and tumor size. Urine cytology was available for 35 patients, of whom 22 (63%) results were false-negative. Upper tract urothelial carcinoma patients had significantly higher Bladder CARE Index values compared to the controls (mean 189.3 vs 1.6, P < .001). The sensitivity, specificity, positive predictive value, and negative predictive value of the Bladder CARE test for detecting upper tract urothelial carcinoma were 96%, 88%, 89%, and 96%, respectively.

Conclusions

Bladder CARE is an accurate urine-based epigenetic test for the diagnosis of upper tract urothelial carcinoma, with much higher sensitivity than standard urine cytology.

Для цитирования: Ghoreifi Alireza, Ladi-Seyedian Seyedeh-Sanam, Piatti Paolo, Chew Yap Ching, Jara Benjamin, Sanossian Lucy, Bhasin Jeffrey M, Yamada Taikun, Fuchs Gerhard, Bhanvadia Sumeet, Sotelo Rene, Hung Andrew, Aron Monish, Desai Mihir, Gill Inderbir, Daneshmand Siamak, Liang Gangning, Djaladat Hooman. A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study.. The Journal of urology. 2023. DOI: 10.1097/ju.0000000000003188.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.